Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuangang Su

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Frontiers in Pharmacology|October 17, 2022
Aminooxyacetic acid hemihydrochloride inhibits osteoclast differentiation and bone resorption by attenuating oxidative phosphorylationBiao Yang, Yuangang Su, Shuai Han, et al.
Phytotherapy Research : PTR|February 15, 2024
Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone lossYansi Xian, Yijie Gao, Yiji Su, et al.
Biochemical Pharmacology|September 7, 2021
Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activationYansi Xian, Yuangang Su, Jiamin Liang, et al.
Drug Design, Development and Therapy|January 14, 2021
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling PathwaysXuedong Li, Xixi Lin, Zuoxing Wu, et al.
Journal of Translational Medicine|January 10, 2026
MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone lossChaofeng Wang, Na Hai, Liuyuan Chen, et al.
International Immunopharmacology|November 3, 2022
AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosisShuyue Yang, Dezhi Song, Ziyi Wang, et al.
Journal of Biochemical and Molecular Toxicology|March 21, 2022
Corilagin attenuates osteoclastic osteolysis by enhancing HO-1 and inhibiting ROSShaolin Tan, Yuangang Su, Linke Huang, et al.
Theranostics|December 11, 2024
Rc3h1 negatively regulates osteoclastogenesis by limiting energy metabolismLiuyuan Chen, Yuangang Su, Chaofeng Wang, et al.
Iscience|September 18, 2023
CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca<sup>2+</sup> oscillations and NF-κB/MAPK signaling pathwaysMinglian Xu, Dezhi Song, Xiaoxiao Xie, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 23, 2025
Brevilin A, a novel BNIP3 inhibitor suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss via impairing mitophagy and mitochondrial metabolismRui Zhou, Yiyuan Wang, Siyi Liu, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Frontiers in Pharmacology|October 17, 2022
Aminooxyacetic acid hemihydrochloride inhibits osteoclast differentiation and bone resorption by attenuating oxidative phosphorylationBiao Yang, Yuangang Su, Shuai Han, et al.
Phytotherapy Research : PTR|February 15, 2024
Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone lossYansi Xian, Yijie Gao, Yiji Su, et al.
Biochemical Pharmacology|September 7, 2021
Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activationYansi Xian, Yuangang Su, Jiamin Liang, et al.
Drug Design, Development and Therapy|January 14, 2021
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling PathwaysXuedong Li, Xixi Lin, Zuoxing Wu, et al.
Journal of Translational Medicine|January 10, 2026
MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone lossChaofeng Wang, Na Hai, Liuyuan Chen, et al.
International Immunopharmacology|November 3, 2022
AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosisShuyue Yang, Dezhi Song, Ziyi Wang, et al.
Journal of Biochemical and Molecular Toxicology|March 21, 2022
Corilagin attenuates osteoclastic osteolysis by enhancing HO-1 and inhibiting ROSShaolin Tan, Yuangang Su, Linke Huang, et al.
Theranostics|December 11, 2024
Rc3h1 negatively regulates osteoclastogenesis by limiting energy metabolismLiuyuan Chen, Yuangang Su, Chaofeng Wang, et al.
Iscience|September 18, 2023
CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca<sup>2+</sup> oscillations and NF-κB/MAPK signaling pathwaysMinglian Xu, Dezhi Song, Xiaoxiao Xie, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 23, 2025
Brevilin A, a novel BNIP3 inhibitor suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss via impairing mitophagy and mitochondrial metabolismRui Zhou, Yiyuan Wang, Siyi Liu, et al.
Pageof 5